Monday, September 21, 2020

SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics

SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics These tablets are indicated as adjunctive therapy for the treatment of partial-onset seizures in patients 12 years of age and older.

from Moneycontrol Business News https://ift.tt/3hR5d9e

No comments:

Post a Comment

Good news for Indian mutual fund investors: SpaceX could join Nasdaq 100 after 15 trading days

SpaceX’s expected entry into the Nasdaq-100 could give Indian investors indirect exposure through Nasdaq-linked mutual funds. Jefferies says...